Compare JD.Com Inc (JD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? JD.Com Inc trades at $26.65 (market cap $36.51B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: JD.Com Inc is far larger — about 37.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and JD.Com Inc pays a 3.73% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 86 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JD | MRVI | |
|---|---|---|
Market Cap | $36.51B | $972.90M |
Volume | 8,583,924 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $9.00 |
52-Week Low | $25.19 | $2.83 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $19.13B | $1.08B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.68, down 0.15% on the day, with a bearish technical signal driven by moving averages. The stock shows strong analyst support with a consensus price target of $35.38 and a 69.57% buy rating. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. Revenue for 2025 reached $1.31 trillion, though net income margin declined to 1.49% from 3.56% in 2024. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, pending EU approval.
JD.com presents a value opportunity with low valuation multiples (P/E of 17.78, P/S of 0.2) and a robust balance sheet featuring $234 billion in cash. However, risks include regulatory scrutiny from EU probes, competitive pressures in Chinese e-commerce, and margin compression. The stock's upside is supported by strong free cash flow and institutional accumulation, but investors must weigh geopolitical and execution risks against the discounted valuation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
